Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Subscribe To Our Newsletter & Stay Updated
